Vascepa Capsule
NDC Package 52937-005-20
Package Information
Vascepa (icosapent ethyl) capsules is vASCEPA® (icosapent ethyl) is indicated:as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and established cardiovascular disease ordiabetes mellitus and 2 or more additional risk factors for cardiovascular disease.as an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.Limitations of Use:The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined. This formulation utilizes a capsule delivery system. Marketed by Amarin Pharma Inc., this product is identified by NDC 52937-005 and is authorized under FDA application NDA202057.
Identification & Billing
- RxCUI: 1304979 - icosapent ethyl 1 GM Oral Capsule
- RxCUI: 1304979 - icosapent ethyl 1000 MG Oral Capsule
- RxCUI: 1304985 - Vascepa 1 GM Oral Capsule
- RxCUI: 1304985 - icosapent ethyl 1000 MG Oral Capsule [Vascepa]
- RxCUI: 1304985 - Vascepa 1000 MG Oral Capsule
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 52937 - Amarin Pharma Inc.
- 52937-005 - Vascepa
- 52937-005-20 - 120 CAPSULE in 1 BOTTLE
- 52937-005 - Vascepa
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 52937-005-20 identifies a specific commercial package of 120 capsule in 1 bottle of Vascepa, a human prescription drug labeled by Amarin Pharma Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 120 billable units per package. This capsule is formulated for oral use and contains icosapent ethyl as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Amarin Pharma Inc. on December 05, 2025. The current certification is valid through December 31, 2027.
How is this Amarin Pharma Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 52937000520. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 120 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.